Renalytix Statistics
Total Valuation
Renalytix has a market cap or net worth of 35.50 million. The enterprise value is 40.12 million.
| Market Cap | 35.50M |
| Enterprise Value | 40.12M |
Important Dates
The next estimated earnings date is Wednesday, March 18, 2026.
| Earnings Date | Mar 18, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
| Current Share Class | n/a |
| Shares Outstanding | n/a |
| Shares Change (YoY) | +182.86% |
| Shares Change (QoQ) | -23.50% |
| Owned by Insiders (%) | 5.64% |
| Owned by Institutions (%) | 70.06% |
| Float | 353.69M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 11.83 |
| PB Ratio | -5.07 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -1.97 |
| EV / Sales | 13.31 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.21
| Current Ratio | 1.21 |
| Quick Ratio | 0.90 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -34.00 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -160.98% |
| Return on Invested Capital (ROIC) | -2,656.25% |
| Return on Capital Employed (ROCE) | -1,307.69% |
| Weighted Average Cost of Capital (WACC) | 12.50% |
| Revenue Per Employee | n/a |
| Profits Per Employee | n/a |
| Employee Count | 102 |
| Asset Turnover | 0.45 |
| Inventory Turnover | 7.20 |
Taxes
| Income Tax | -1.40M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -33.83% in the last 52 weeks. The beta is 1.83, so Renalytix's price volatility has been higher than the market average.
| Beta (5Y) | 1.83 |
| 52-Week Price Change | -33.83% |
| 50-Day Moving Average | 4.31 |
| 200-Day Moving Average | 4.88 |
| Relative Strength Index (RSI) | 53.57 |
| Average Volume (20 Days) | 2,564 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Renalytix had revenue of 3.00 million and -20.40 million in losses. Loss per share was -0.07.
| Revenue | 3.00M |
| Gross Profit | 1.20M |
| Operating Income | -17.00M |
| Pretax Income | -21.80M |
| Net Income | -20.40M |
| EBITDA | -16.80M |
| EBIT | -17.00M |
| Loss Per Share | -0.07 |
Balance Sheet
The company has 3.70 million in cash and 8.30 million in debt, with a net cash position of -4.60 million.
| Cash & Cash Equivalents | 3.70M |
| Total Debt | 8.30M |
| Net Cash | -4.60M |
| Net Cash Per Share | n/a |
| Equity (Book Value) | -7.00M |
| Book Value Per Share | -0.02 |
| Working Capital | 1.00M |
Cash Flow
| Operating Cash Flow | -17.90M |
| Capital Expenditures | n/a |
| Free Cash Flow | n/a |
| FCF Per Share | n/a |
Margins
| Gross Margin | 40.00% |
| Operating Margin | -566.67% |
| Pretax Margin | -726.67% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Renalytix does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -182.86% |
| Shareholder Yield | -182.86% |
| Earnings Yield | -57.47% |
| FCF Yield | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on December 16, 2025. It was a reverse split with a ratio of 0.04.
| Last Split Date | Dec 16, 2025 |
| Split Type | Reverse |
| Split Ratio | 0.04 |
Scores
Renalytix has an Altman Z-Score of -44.88 and a Piotroski F-Score of 4. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -44.88 |
| Piotroski F-Score | 4 |